By Angus Liu
In the past few weeks, anti-vaxxers have rallied behind a nonpeer-reviewed study by a group of Canadian researchers as evidence against COVID-19 vaccines. Turns out, the paper made a fatal mistake in reaching its conclusion.
read more
By Beth Snyder Bulik
After a year when it seems like creativity should have hit a pause, the Fierce Pharma Marketing Award winners are proof of just the opposite.
read more
By Kyle LaHucik
Just five months after debuting with a nanobody licensed from Merck KGaA, MoonLake Immunotherapeutics is headed to Wall Street. The Swiss biotech is linking arms with blank-check company Helix Acquisition in a SPAC deal that will give MoonLake $230 million in proceeds.
read more
By Conor Hale
Labcorp aims to tackle both infections with a single test, with an at-home collection kit for gathering samples from children as young as two years old.
read more
By Arlene Weintraub
Michigan State University researchers discovered that glial cells actively modify electrical signals in the gut to maintain normal functions like motility. They believe the findings could inspire new treatments for common conditions like inflammatory bowel disease and other motility disorders.
read more
By Paige Minemyer
Humana is launching 72 new Medicare Advantage plans for 2022 across hundreds of additional counties, the insurer announced Friday.
read more
By Andrea Park
The brain stimulation system includes a small device implanted on the patient’s brain that continuously monitors neurological activity and instructs two leads in separate areas of the brain to emit pulses if abnormal activity is detected.
read more
By Kyle LaHucik
Anatara Lifesciences is joining the decentralized clinical trials movement. The Australian company will test a microbiome-targeted medicine for patients who have irritable bowel syndrome with diarrhea using in-home data through a partnership with ObvioHealth.
read more
By Natalie Missakian
Rare disease patients, like many, are seeing pharma companies in a better light these days, but there’s still a need for transparency, fairer pricing and more patient engagement, according to a survey of 230 rare disease patient advocacy groups.
read more
.png)
